Alzheimer’s Disease

Opening — Why this matters now Healthcare AI has spent years trying to look impressive in carefully lit laboratory conditions. Alzheimer’s disease, with its irregular follow-ups, missing scans, incomplete biomarkers, and deeply uneven patient trajectories, is less polite. It is not a clean benchmark. It is a bureaucracy of biology. That is why the arXiv paper “CognitiveTwin: Robust Multi-Modal Digital Twins for Predicting Cognitive Decline in Alzheimer’s Disease” deserves attention.1 It does not merely ask whether a model can classify Alzheimer’s disease from a snapshot. That problem is already crowded, noisy, and occasionally dressed up as clinical transformation. Instead, the paper asks a harder and more operationally relevant question: can an AI system model an individual patient’s cognitive trajectory over time, using fragmented clinical evidence, while remaining accurate, calibrated, and fair across demographic groups? ...

Glue sounds almost too gentle for Alzheimer’s disease. The usual business pitch for AI drug discovery prefers a louder vocabulary: acceleration, disruption, de-risking, platform advantage, and occasionally “revolution,” because apparently no investor memo can survive without one. This paper is more interesting when read against that noise. It does not show that AI has found an Alzheimer’s drug. It does not show that amyloid-β42 has been degraded in cells. It does not show brain delivery, toxicity control, animal efficacy, or clinical relevance. ...

When Attention Learns to Breathe: Sparse Transformers for Sustainable Medical AI Hospital AI does not fail only because models are inaccurate. It also fails because the input is messy, the compute budget is limited, the deployment environment is not a research lab, and the missing field in the patient record is somehow always the one the model wanted most. Elegant, really. ...